| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1172/JCI111389 |
| P953 | full work available at URL | http://www.jci.org/articles/view/111389/files/pdf |
| https://europepmc.org/articles/PMC425178 | ||
| https://europepmc.org/articles/PMC425178?pdf=render | ||
| P932 | PMC publication ID | 425178 |
| P698 | PubMed publication ID | 6330171 |
| P5875 | ResearchGate publication ID | 16866460 |
| P2093 | author name string | R. D. Rosenberg | |
| J. S. Rosenberg | |||
| P2860 | cites work | Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis | Q24338122 |
| Deficiency of protein C in congenital thrombotic disease | Q24600822 | ||
| Protein C inhibitor. Purification from human plasma and characterization | Q28264952 | ||
| Studies of the capacity of factor Xa to protect factor Va from inactivation by activated protein C | Q28275580 | ||
| INHERITED ANTITHROMBIN DEFICIENCY CAUSING THROMBOPHILIA | Q34261019 | ||
| Preparation and properties of bovine factor VIII (antihemophilic factor). | Q34285283 | ||
| Synthesis of fibrinolytic activator and inhibitor by endothelial cells | Q35051369 | ||
| Protection of factor Xa from neutralization by the heparin-antithrombin complex | Q35207027 | ||
| Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. | Q35345503 | ||
| Multiple functional domains of the heparin molecule | Q35416424 | ||
| Differentiated microdomains on the luminal surface of the capillary endothelium. II. Partial characterization of their anionic sites | Q36205324 | ||
| Antithrombin III Toyama: replacement of arginine-47 by cysteine in hereditary abnormal antithrombin III that lacks heparin-binding ability | Q36246347 | ||
| Circular dichroism spectroscopy of heparin-antithrombin interactions | Q36322607 | ||
| Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin | Q36414932 | ||
| Activation of Protein C In Vivo | Q36985264 | ||
| Generation of fibrinolytic activity by infusion of activated protein C into dogs | Q37005184 | ||
| Identification in vitro of an endothelial cell surface cofactor for antithrombin III. Parallel studies with isolated perfused rat hearts and microcarrier cultures of bovine endothelium | Q37008999 | ||
| Sequence of Fibrinogen Proteolysis and Platelet Release after Intrauterine Infusion of Hypertonic Saline | Q37017511 | ||
| Circulating heparan sulfate proteoglycan anticoagulant from a patient with a plasma cell disorder | Q37021334 | ||
| Clearance of thrombin from circulation in rabbits by high-affinity binding sites on endothelium. Possible role in the inactivation of thrombin by antithrombin III | Q37026391 | ||
| Effect of thrombin on the fibrinolytic activity of cultured bovine endothelial cells | Q37040070 | ||
| Human plasma protein C: isolation, characterization, and mechanism of activation by alpha-thrombin | Q37041393 | ||
| Abnormal plasminogen. A hereditary molecular abnormality found in a patient with recurrent thrombosis | Q37053493 | ||
| Correlation between structure and function of heparin | Q37320355 | ||
| Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex | Q37510853 | ||
| Structure-function relationships of heparin species | Q37589663 | ||
| Inhibition of activated factor XII by antithrombin-heparin cofactor | Q39404087 | ||
| Amino acid sequence studies on plasmin-derived fragments of human fibrinogen. Amino-terminal sequences of intermediate and terminal fragments | Q39731712 | ||
| Enzymatic degradation of heparin-related mucopolysaccharides from the surface of endothelial cell cultures | Q39731799 | ||
| The primary inhibitor of plasmin in human plasma | Q39798582 | ||
| Relative proteolysis of the fibrinogen B beta chain by thrombin and plasmin as a determinant of thrombosis | Q41574733 | ||
| Purification of human vitamin K-dependent protein S and its limited proteolysis by thrombin | Q42167364 | ||
| Familial thrombosis due to antithrombin 3 deficiency | Q47894264 | ||
| The Purification and Mechanism of Action of Human Antithrombin-Heparin Cofactor | Q47962380 | ||
| Hereditary dysfibrinogenemia in a patient with thrombotic disease | Q54493851 | ||
| Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. | Q55062462 | ||
| Anticoagulant Action of Heparin | Q59048517 | ||
| Inherited antithrombin-III deficiency causing mesenteric venous infarction: a new clinical entity | Q66941583 | ||
| The inhibition of blood coagulation by activated protein C through the selective inactivation of activated factor V | Q66971115 | ||
| Inhibition of human factor IXa by human antithrombin | Q67340338 | ||
| A family with thromboembolic disease associated with deficient fibrinolytic activity in vessel wall | Q67348704 | ||
| Isolation and characterization of urokinase from human plasma | Q70219580 | ||
| Microvascular heparin-like species with anticoagulant activity | Q70298440 | ||
| Venous thrombosis in a family with defective release of vascular plasminogen activator and elevated plasma factor VIII/von Willebrand's factor | Q70424357 | ||
| Regulation of activated protein C by protein S. The role of phospholipid in factor Va inactivation | Q70556596 | ||
| Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn | Q70811173 | ||
| Abnormal plasminogen, a case of recurrent thrombosis | Q70890388 | ||
| Antithrombin III Toyama: a hereditary abnormal antithrombin III of a patient with recurrent thrombophlebitis | Q71085495 | ||
| The light chain of factor Va contains the activity of factor Va that accelerates protein C activation by thrombin | Q71245008 | ||
| Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families | Q71245149 | ||
| Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture | Q71552950 | ||
| Inhibitory effect of activated protein C on activation of prothrombin by platelet-bound factor Xa | Q71849254 | ||
| Functional properties of an endothelial cell cofactor for thrombin-catalyzed activation of protein C | Q71854044 | ||
| Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C | Q71857877 | ||
| Amino acid sequence of the light chain of bovine protein C | Q71861539 | ||
| The active site of antithrombin. Release of the same proteolytically cleaved form of the inhibitor from complexes with factor IXa, factor Xa, and thrombin | Q72103528 | ||
| Thrombin and plasmin activity and platelet activation in the development of venous thrombosis | Q72776609 | ||
| Anticoagulantly active heparin-like molecules from vascular tissue | Q72814587 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | blood coagulation | Q179217 |
| anticoagulant | Q215118 | ||
| anticoagulation | Q63279445 | ||
| P304 | page(s) | 1-6 | |
| P577 | publication date | 1984-07-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Natural anticoagulant mechanisms | |
| P478 | volume | 74 |
| Q26700126 | A Novel Interaction between Complement Inhibitor C4b-binding Protein and Plasminogen That Enhances Plasminogen Activation |
| Q35564946 | A brief historical review of the waterfall/cascade of blood coagulation |
| Q73305518 | A new model of human aortic endothelial cells in vitro |
| Q73343732 | A synthetic selective inhibitor of factor Xa, DX-9065a, reduces monocyte chemoattractant protein-1 expression after ischemia-reperfusion injury in rat liver |
| Q36213145 | Activation of coagulation releases endothelial cell mitogens |
| Q36994546 | Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator |
| Q39636448 | An overview of hemostasis |
| Q37283042 | Annexin A2: biology and relevance to the antiphospholipid syndrome |
| Q71214953 | Anticoagulant pretreatment attenuates production of cytokine-induced neutrophil chemoattractant following ischemia-reperfusion of rat liver |
| Q33416855 | Antiphospholipid antibodies and recurrent pregnancy loss |
| Q69712983 | Antithrombin III activity (residual thrombin activity) in plasma from non-medicated or heparinized horses |
| Q33888171 | Antithrombotic and prothrombotic activities of the vascular endothelium |
| Q68016411 | Benefits and risks of antithrombin III concentrates |
| Q35108747 | Child witnesses to domestic violence: A meta-analytic review |
| Q33411302 | Clinical efficacy of heparin fractions: issues and answers |
| Q39608549 | Coagulation, inflammation, and responses to injury. |
| Q34479488 | Cutaneous small-vessel vasculitis |
| Q58960831 | EVALUATION OF A NEW SCREENING ASSAY PROC® GLOBAL FOR IDENTIFICATION OF DEFECTS IN THE PROTEIN C/PROTEIN S ANTICOAGULANT PATHWAY |
| Q42802874 | Effect of a heparan sulphate with high affinity for antithrombin III upon inactivation of thrombin and coagulation factor Xa |
| Q53763072 | Electrical injury in the femoral artery of rabbits as a model for arterial thrombosis: a pilot study. |
| Q41852417 | Endothelial binding sites for heparin. Specificity and role in heparin neutralization |
| Q73934638 | Endothelial-derived nitric oxide preserves anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells |
| Q33665374 | Enhanced thrombin generation and platelet binding on herpes simplex virus-infected endothelium |
| Q39627516 | Enzyme linked immunosorbent assay for measuring antithrombin III. |
| Q41936652 | Factor V has an anticoagulant cofactor activity that targets the early phase of coagulation. |
| Q69996235 | Fibrinogen--proteolysis in acute myelogenous leukemia (AML) |
| Q70721508 | Glycosaminoglycans exposed on the endothelial cell surface. Binding of heparin-like molecules derived from serum |
| Q70065691 | Heparan sulphate with no affinity for antithrombin III and the control of haemostasis |
| Q38574126 | Heparins in ulcerative colitis: proposed mechanisms of action and potential reasons for inconsistent clinical outcomes |
| Q47683800 | Hereditary Thrombophilic Disease Associated with Defects in the Protein C Anticoagulant System |
| Q22254095 | High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II |
| Q40304955 | Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells |
| Q37967568 | Human cytomegalovirus infection and atherothrombosis |
| Q77530332 | Human endothelial cells do not exert heparin like accelerating effects on thrombin-antithrombin-complex formation |
| Q36480208 | Hypotension and inflammatory cytokine gene expression triggered by factor Xa-nitric oxide signaling |
| Q41693308 | Immunology of xenotransplantation |
| Q41024567 | Laboratory diagnosis of hemorrhagic and thrombotic disorders. |
| Q28654633 | Macromolecular approaches to prevent thrombosis and intimal hyperplasia following percutaneous coronary intervention |
| Q37912981 | Microvascular endothelial cell heterogeneity: interactions with leukocytes and tumor cells |
| Q42151543 | Modulation of endothelial cell hemostatic properties by tumor necrosis factor |
| Q37223789 | Molecular Biology of Cytokine Effects on Vascular Endothelial Cells |
| Q41058646 | Monocyte chemoattractant protein-1 enhances expression of intercellular adhesion molecule-1 following ischemia-reperfusion of the liver in rats |
| Q40774985 | New biological concepts on coagulation inhibitors |
| Q41238308 | Optical sensing of anticoagulation status: Towards point-of-care coagulation testing |
| Q35977647 | Oral direct thrombin inhibition: an effective and novel approach for venous thromboembolism |
| Q36090960 | Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Proteins in Urothelial Cell Carcinoma of Human Bladder |
| Q38677389 | Placental fibrin |
| Q36216672 | Plasmalemmal proteins of cultured vascular endothelial cells exhibit apical-basal polarity: analysis by surface-selective iodination |
| Q73635480 | Platelet and Thrombin Activity Following Cardiac Catheterization Despite Treatment with Aspirin |
| Q33635802 | Platelet-dependent and procoagulant mechanisms in arterial thrombosis. |
| Q35239901 | Polysulfated trehalose as a novel anticoagulant agent with dual mode of action |
| Q67883906 | Possible role of vascular intima for generation of coagulant activity in patients undergoing coronary thrombolysis with recombinant tissue-type plasminogen activator. A randomized, placebo-controlled study |
| Q69925034 | Protein C deficiency and portal thrombosis in liver transplantation in children |
| Q68004018 | Pulmonary embolism in the elderly |
| Q92874976 | Recombinant human soluble thrombomodulin is associated with attenuation of sepsis-induced renal impairment by inhibition of extracellular histone release |
| Q68104220 | Recurrent renal vein thrombosis and renal failure associated with antithrombin-III deficiency |
| Q51431144 | Regulation of thrombin generation by TFPI in plasma without and with heparin. |
| Q73039117 | Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II |
| Q35160253 | Selective factor Xa inhibition improves efficacy of venous thromboembolism prophylaxis in orthopedic surgery |
| Q73279715 | Soluble complement receptor type 1 and antithrombin-III combination therapy prolongs xenograft survival: the role of thrombin and prostacyclin in hyperacute rejection |
| Q30486405 | Soluble thrombomodulin protects ischemic kidneys |
| Q33367033 | Synthetic and recombinant antithrombin drugs |
| Q36121888 | The C-terminal fragment of axon guidance molecule Slit3 binds heparin and neutralizes heparin's anticoagulant activity |
| Q34103306 | The N-terminal epidermal growth factor-like domain in factor IX and factor X represents an important recognition motif for binding to tissue factor |
| Q32043322 | The antithrombotic effect of potent bifunctional thrombin inhibitors based on hirudin sequence, P551 and P532, on He-Ne laser-induced thrombosis in rat mesenteric microvessels |
| Q37742508 | The endothelium: physiological functions and role in microcirculatory failure during severe sepsis |
| Q41910544 | The hyperglycemic byproduct methylglyoxal impairs anticoagulant activity through covalent adduction of antithrombin III. |
| Q42154755 | The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin |
| Q55060438 | The regulation of natural anticoagulant pathways. |
| Q69785983 | The use of antithrombotic therapy in the elderly |
| Q40388242 | The vascular endothelium in septic shock. |
| Q90053693 | Therapeutic strategies for thrombosis: new targets and approaches |
| Q42481569 | Thrombin Regulates Expression of Monocyte Chemoattractant Protein-1 in Vascular Smooth Muscle Cells |
| Q28246124 | Thrombin and vascular inflammation |
| Q30449306 | Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor |
| Q73966288 | Thrombophilia found in patients with moyamoya disease |
Search more.